Marinus Pharmaceuticals — Q3 2021 Earnings Presentation
78 slides from Marinus Pharmaceuticals's earnings presentation, Nov 9, 2021
Slide 1: Corporate Presentation November 2021
©2021 Marinus Pharmaceuticals. All Rights Reserved I Corporate Presentation November 2021
Slide 2: Forward-looking statements
©2021 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking statements reflecting the current beliefs and expectations of management made pursuant to the safe
Slide 3: Compelling Therapeutic Profile & Differentiated MOA
©2021 Marinus Pharmaceuticals. All Rights Reserved I Compelling Therapeutic Profile & Differentiated MOA Building Upon A Strong Foundation and Differentiated Product Profile To Achieve Long - term Value Creation IV Oral Second Generation Formulation Explore Unmet Medical Need in Rare Epilepsies and
Slide 4: Ganaxolone Development Pipeline
©2021 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Development Pipeline PDUFA date March 2022 MAA filing validation Q4 2021 Ph3 patient enrollment Q1 2022 Topline data 1H 2024 GANAXOLONE Phase 1 Phase 2 Phase 3 Anticipated Milestones Oral Suspension Intravenous Clinical Development Intr
Slide 5: Orphan Epilepsy Oral Ganaxolone Franchise
Orphan Epilepsy Oral Ganaxolone Franchise
Slide 6: Building an Oral Ganaxolone Franchise
©2021 Marinus Pharmaceuticals. All Rights Reserved I ► Clinical data from the Marigold study in CDD highlight the potential for ganaxolone in treatment - resistant rare epilepsies • Pharmacokinetic - pharmacodynamic data suggest opportunities for formulation R&D Building an Oral Ganaxolone Franchise
Slide 7: CDKL5 Deficiency Disorder
CDKL5 Deficiency Disorder “CDKL5 is painful. It’s a hard, sad at times, thing that we face. When you have a relationship with people like Marinus and their researchers, you are able to help be a driving force behind that work. - Karen Utley, Mother to Samantha, President of International Foundation
Slide 8: CDKL5 Deficiency Disorder (CDD)
©2021 Marinus Pharmaceuticals. All Rights Reserved I Cause • Mutation of the cyclin - dependent kinase - like 5 (CDKL5) gene, located on the X chromosome Symptoms • Early - onset, treatment refractory seizures, & severe neuro - developmental delay • Most can’t walk, talk or care for themselves • Suf
Slide 9: Completed Global Phase 3 Trial Design
©2021 Marinus Pharmaceuticals. All Rights Reserved I 9 Completed Global Phase 3 Trial Design Baseline 6 weeks Historical Control 8 weeks Double - Blind Phase Open - Label Phase Maintenance 13 weeks Titration 4 weeks Open - Label Phase ► Trial Details • Evaluated the use of oral ganaxolone in childre
Slide 10: Ganaxolone Achieved Primary Efficacy Endpoint in Seizure Reduction
©2021 Marinus Pharmaceuticals. All Rights Reserved I 10 Ganaxolone Achieved Primary Efficacy Endpoint in Seizure Reduction and Secondary Endpoint for Seizure Severity Caregiver Global Impression of Change in Seizure Intensity / Duration (CGI - CSID) Ganaxolone Placebo 0 10 20 30 40 M e d i a n P e r
Slide 11: Durable Seizure Improvements in the Open Label Extension
©2021 Marinus Pharmaceuticals. All Rights Reserved I 11 Ganaxolone’s Potential to Provide Durable Seizure Improvements in the Open Label Extension Seizures associated with CDD are often refractory to treatment with existing AEDs and improvements may be short - lived (<3 months) 1 Preliminary analysi
Slide 12: Phase 3 Safety Summary
©2021 Marinus Pharmaceuticals. All Rights Reserved I 12 Phase 3 Safety Summary Treatment Emergent Adverse Events (TEAE) Preferred Term Placebo (n=51) Ganaxolone (n=50) Any TEAE, n (%) 45 (88.2) 43 (86.0) Somnolence 8 (15.7) 18 (36.0) Pyrexia 4 (7.8) 9 (18.0) Upper Respiratory Tract Infection 3 (5.9)
Slide 13: CDD Commercial Preparedness
CDD Commercial Preparedness
Slide 14: CDD Commercial Strategic Launch Imperatives
©2021 Marinus Pharmaceuticals. All Rights Reserved I CDD Commercial Strategic Launch Imperatives Establish Ganaxolone as central to comprehensive management of CDD Build foundational commercial infrastructure that enables scalability Establish Marinus as a trusted partner in the CDD community Develo
Slide 15: Anticipated Commercial Launch Plan - CDD
©2021 Marinus Pharmaceuticals. All Rights Reserved I Q3 - Q4 ‘21 Q1 - Q2 ‘22 Q3 - Q4 ‘22 Anticipated Commercial Launch Plan - CDD NDA Filed *Approval *Launch Inventory Build Product Ready for Sale Initial Payer Engagement Specialty Pharmacy On - boarded Pricing Field Size & Structure Formulary Cover
Slide 16: U.S. Anticipated Launch Timeline - CDD
©2021 Marinus Pharmaceuticals. All Rights Reserved I U.S. Anticipated Launch Timeline - CDD CDD Targeted Launch June 2022* Commercial Launch Plan Execution End of 2022 ► Access: • Ganaxolone added to formulary in major commercial plans • State Medicaid Access • Execution of patient services ► Patien
Slide 17: Targeted Sales Force Team & Key Account Strategy - CDD
©2021 Marinus Pharmaceuticals. All Rights Reserved I Targeted Sales Force Team & Key Account Strategy - CDD CDD ‘A’ Accounts (40) • Largest # of patient claims • Early adopters • High influence CDD ‘B’ Accounts (47) • Large # of patient claims • Delayed adoption • High influence CDD ‘C’ Accounts (17
Slide 18: Market Access Strategy: Optimize Access for Oral Suspension - CDD
©2021 Marinus Pharmaceuticals. All Rights Reserved I Market Access Strategy: Optimize Access for Oral Suspension - CDD • US/EU pricing research conducted – final pricing analysis underway; based and reflective of traditional symptomatic ultra orphan disease treatments • Finalizing: government pricin
Slide 19: Tuberous Sclerosis Complex
Tuberous Sclerosis Complex “Many individuals with TSC continue to experience uncontrolled seizures despite a cocktail of multiple antiepileptic drugs. Because new options are always needed, the TSC community welcomes clinical evaluation of new epilepsy treatments” - Kari Luther Rosbeck , President &
Slide 20: Tuberous Sclerosis Complex (TSC)
©2021 Marinus Pharmaceuticals. All Rights Reserved I 20 Tuberous Sclerosis Complex (TSC) 1 diMichele, et al, J. Neuro Neurosurg Psychiatry , 2003 *Failure of two prior antiseizure medications with ongoing, frequent seizures. Cause • Defect or mutation of TSC1 and/or TSC2 genes Symptoms • Benign tumo
Slide 21: Ganaxolone in TSC: Phase 2 Design
©2021 Marinus Pharmaceuticals. All Rights Reserved I PART A PART B Baseline (4 Weeks) GNX Titration (4 Weeks) GNX Maintenance (8 Weeks) Open - Label Extension (OLE) (24 Weeks) * Available to patients that respond to GNX as defined per protocol Ganaxolone in TSC: Phase 2 Design BASELINE PERIOD TREATM
Slide 22: Percent Reduction in TSC-associated Seizure Frequency
©2021 Marinus Pharmaceuticals. All Rights Reserved I Percent Reduction in TSC - associated Seizure Frequency -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 P e r c e n t r e d u c t i o n i n T S C - a s s o c i a t e d s e i z u r e f r e q u e n c y =median 16.6% -20 0 20 40 60 80 100 Percent reducti
Slide 23: Phase 2 Secondary and Exploratory Analyses
©2021 Marinus Pharmaceuticals. All Rights Reserved I Phase 2 Secondary and Exploratory Analyses Proportion of patients with a ≥50% reduction in TSC - associated seizure frequency Percent reduction on focal seizures * Secondary endpoint * Intent to Treat (n=23) +Cannabidiol (n=12) +Everolimus (n=11)
Slide 24: TSC Phase 2 Safety & Tolerability
©2021 Marinus Pharmaceuticals. All Rights Reserved I TSC Phase 2 Safety & Tolerability Ganaxolone was generally well - tolerated with somnolence reported as the most common adverse event consistent with previous studies • Four patients (17.4%) discontinued due to adverse events PREFERRED TERM Ganaxo
Slide 25: Association Between Early Tolerability and Efficacy
©2021 Marinus Pharmaceuticals. All Rights Reserved I Association Between Early Tolerability and Efficacy Non - somnolence - related - AE patients experienced directionally better seizure reductions… Responders had fewer dose adjustments… Responders Non - responders *includes 7 patients with ≥ 45% re
Slide 26: Concomitant Epidiolex Use Linked to Greater Somnolence
©2021 Marinus Pharmaceuticals. All Rights Reserved I Concomitant Epidiolex ® Use Appear to be Linked to Greater Somnolence and Early Elevation of Ganaxolone Blood Levels Epidiolex ® is a registered trademark of GW RESEARCH LIMITED. r s = 0.700 p = 0.016 Spearman’s Correlation *PK samples obtained at
Slide 27: Phase 3 Protocol Refinements
©2021 Marinus Pharmaceuticals. All Rights Reserved I 0 7 14 21 28 0 20 40 60 80 100 Time (days) A p p r o x . % M a x G N X D o s e ( b a s e d o n ' e x i s t i n g t i t r a t i o n ' ) Existing Titration TSC Ph3: Non- & Low-Dose Epidiolex® TSC Ph3: Remaining patients on Epidiolex® Phase 3 Protoco
Slide 28: Additional Phase 3 Protocol Refinements Informed by Phase 2
©2021 Marinus Pharmaceuticals. All Rights Reserved I Additional Phase 3 Protocol Refinements Informed by Phase 2 ► Partner more closely with the Epilepsy Study Consortium • Clarifying definitions of countable primary endpoint seizures • Incorporating relevant clinical and diagnostic test data are co
Slide 29: Phase 3 Study Overview
©2021 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Study Overview ► Enrollment: ~162 patients, 60 U.S and western Europe total sites (targeting EU enrollment ~25% of study) ► Primary Endpoint: Percent change in TSC - associated seizure frequency ► Key Secondary Endpoints: Percent change in
Slide 30: Second Generation Product Development
Second Generation Product Development
Slide 31: Second Generation Formulation
©2021 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Formulation Improved bioavailability Reduced variability Ability to dose titrate Improved patient convenience • First candidate in clinic Q1 2022 • Second candidate in clinic by mid - 2022 • Selection of prodrug candidate by mid
Slide 32: Rationale and Objectives for Second Generation Formulation
©2021 Marinus Pharmaceuticals. All Rights Reserved I Rationale and Objectives for Second Generation Formulation Superior Efficacy – Achieve target blood levels to drive better clinical response Improved Safety Profile - Smoother PK to mitigate somnolence levels Reduced Dosing Frequency – More sustai
Slide 33: Drug Exposure is Critical in Treatment of Chronic Epilepsies
©2021 Marinus Pharmaceuticals. All Rights Reserved I Drug Exposure is Critical in Treatment of Chronic Epilepsies Age Group AUC 24 (ng* hr /mL) C min (ng/mL) C max (ng/mL) 2 to <6 years 3903 85 247 6 to <12 years 3998 84 269 12 to <18 yrs 4106 84 293 ≥18 years 4100 84 292 Abbreviations: AUC 24 =24 -
Slide 34: Average Ganaxolone Levels Correlate with Seizure Reduction
©2021 Marinus Pharmaceuticals. All Rights Reserved I Average Ganaxolone Levels Correlate with Seizure Reduction • Logarithms of plasma GNX level and percentage change in major motor seizure frequency were negatively correlated • Patients in the Medium and High GNX level groups had an average GNX con
Slide 35: Second Generation Formulation Target PK Parameters
©2021 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Formulation Target PK Parameters • Increase absorption to achieve target exposure (AUC) • Increase the proportion of time plasma concentration exceeds the nominal minimally effective concentration (MEC) • Avoid significant increa
Slide 36: Second Generation Formulation Development Approach
©2021 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Formulation Development Approach Reformulation Strategy: Key Progress: ► 5 shortlisted candidate formulations under CMC and preclinical evaluation • 2 candidates selected for clinical and regulatory development • Additional back
Slide 37: Second Generation Candidate Promises Enhanced Exposure
©2021 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Candidate Promises Enhanced Exposure ► In one of the shortlisted formulations: • Single dose administration in rats delivered 6 - 10 - fold increase in Cmax and 2 - 5 - fold increase in AUC ► Species is a model very translatable
Slide 38: Development Options for Second Generation in New Indication
©2021 Marinus Pharmaceuticals. All Rights Reserved I ► Clinical development plan will be designed to: • Quickly evaluate multiple candidates for the key PK parameters • Be opportunistic about early entry to Phase 2 (likely LGS), or to deepen PK insights for a potentially rapid move to a pivotal tria
Slide 39: Prodrug Development Approach
©2021 Marinus Pharmaceuticals. All Rights Reserved I Prodrug Development Approach Opportunity Improve Product Profile Applicability to Both Oral and IV New Composition of Matter IP Protection Flexibility for IV Franchise Challenge No ganaxolone prodrugs have been developed and conventional approache
Slide 40: Acute Seizure Disorders Intravenous (IV) Ganaxolone Franchise
Acute Seizure Disorders Intravenous (IV) Ganaxolone Franchise
Slide 41: Status Epilepticus
©2021 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus
Slide 42: Status Epilepticus (SE): Definition and Epidemiology
©2021 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus (SE): Definition and Epidemiology Background ► Prolonged continuous or near - continuous seizures ► Heterogeneous patient population with etiologies that include brain tumors, stroke, encephalitis, drug or alcohol withdrawal or
Slide 43: Strategic Approach to SE Clinical Development
©2021 Marinus Pharmaceuticals. All Rights Reserved I Strategic Approach to SE Clinical Development Benzodiazepine Administered (Medically induced Coma) Established Status Epilepticus (ESE) IV AEDs (antiepileptic drugs) IV Anesthetics Super Refractory Status Epilepticus (SRSE) Refractory Status Epile
Slide 44: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment
©2021 Marinus Pharmaceuticals. All Rights Reserved I 44 Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment Experimental PK – plasma and brain 1 Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice Human PD – EEG changes 2 EEG bispectral index in healthy volunteers fol
Slide 45: Refractory Status Epilepticus Phase 2 Trial Design
©2021 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper 45 Phase 2 Refractory Status Epilepticus Trial Design Diagnosis of convulsive or non - convulsive SE Failed at least one 2 nd line IV AED but had not progressed to 3 rd line IV anesthetics Bolus plus
Slide 46: Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect
©2021 Marinus Pharmaceuticals. All Rights Reserved I 46 Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status - free through 24 hours from infusion initiation (investigator det
Slide 47: PK/PD Relationship and Rationale for Target Dose
©2021 Marinus Pharmaceuticals. All Rights Reserved I 47 PK/PD Relationship and Rationale for Target Dose Seizure Burden Reduction Occurred Rapidly in All Dose Groups Modeled PK Curves for All Dose Groups High Dose Achieves Target Range ≥ 500 ng/mL for ~8 hours Only High Dose Provided Sustained Reduc
Slide 48: IV Ganaxolone Safety Summary
©2021 Marinus Pharmaceuticals. All Rights Reserved I 48 IV Ganaxolone Safety Summary Intubation: 9 patients were not intubated upon enrollment. Of these, 6 remained intubation - free during the entire ganaxolone treatment period Data presented at AES 2019 AE: adverse event / SAE: serious adverse eve
Slide 49: U.S. RSE Phase 3 RAISE Trial Design
©2021 Marinus Pharmaceuticals. All Rights Reserved I U.S. RSE Phase 3 RAISE Trial Design Ganaxolone development for RSE is being funded, in part, by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the
Slide 50: RAISE Site Locations
©2021 Marinus Pharmaceuticals. All Rights Reserved I RAISE Site Locations (As of November 5) Current & Anticipated High Enrollers Activated: • Brigham and Women's Hospital • Carle Foundation Hospital • Washington University School of Medicine • Oregon Health and Science University • Rancho Research
Slide 51: Status Epilepticus Development Plan
©2021 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus Development Plan
Slide 52: Expanding the Ganaxolone Opportunity in Status Epilepticus
©2021 Marinus Pharmaceuticals. All Rights Reserved I Expanding the Ganaxolone Opportunity in Status Epilepticus RESET Trial Established Status Epilepticus • Access broader patient population earlier in continuum • 75,000 ESE patients per year (~2x RSE population) ¹ , ² • Study in ER setting in patie
Slide 53: Strategic Approach to SE Clinical Development
©2021 Marinus Pharmaceuticals. All Rights Reserved I Strategic Approach to SE Clinical Development Benzodiazepine Administered (Medically induced Coma) Established Status Epilepticus (ESE) IV AEDs (antiepileptic drugs) IV Anesthetics Super Refractory Status Epilepticus (SRSE) Refractory Status Epile
Slide 54: Treatment of Refractory Status Epilepticus: RAISE vs. RAISE II
©2021 Marinus Pharmaceuticals. All Rights Reserved I 54 Emergency Room ICU Tertiary Center ICU Treatment of Refractory Status Epilepticus: RAISE vs. RAISE II RAISE Trial: Failure of benzodiazepines and two or more second line AEDs RAISE II Trial: • Failure of benzodiazepines and initial second line
Slide 55: Proposed Phase 3 Trial in Refractory SE (RAISE II)
©2021 Marinus Pharmaceuticals. All Rights Reserved I Trial Goals: • Support potential European approval in RSE • Potential indication expansion opportunity (relative to the RAISE trial population) Proposed Phase 3 Trial in Refractory SE (RAISE II) TRIAL ATTRIBUTES Trial Population Failure of benzodi
Slide 56: RESET: Phase 3 Trial in Established Status Epilepticus
©2021 Marinus Pharmaceuticals. All Rights Reserved I RESET: Phase 2 Trial in Established Status Epilepticus 1 Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus N Engl J Med 2019;381:2103 - 13. Key Trial points: • Patients with convulsive status epilepticus • Ne
Slide 57: RESET Trial in Established Status Epilepticus
©2021 Marinus Pharmaceuticals. All Rights Reserved I Screening <30 min Double - blind Phase Enrollment Placebo IV GNX RESET Trial in Established Status Epilepticus Fail BZD IV GNX infusion 1 IV GNX infusion 3 SOC IV AED Convulsive SE (N=40) GNX Bolus GNX Bolus GNX Bolus Seizures YES NO Seizures YES
Slide 58: Building Commercial Infrastructure for Future IV Launches
Building Commercial Infrastructure for Future IV Launches
Slide 59: Defining the Economic Burden in Status Epilepticus
©2021 Marinus Pharmaceuticals. All Rights Reserved I The Phase 3 study of GNX in refractory SE aims to demonstrate rapid onset of action capable of preventing escalation of treatment to IV anesthesia Treatment of refractory SE with IV anesthetics has been reported to lead to increased length of hosp
Slide 60: Clinical and Healthcare Costs Associated with RSE
©2021 Marinus Pharmaceuticals. All Rights Reserved I Treatments that prevent progression to SRSE with its associated complications may reduce length of stay and hospital costs Clinical and Healthcare Costs Associated with RSE GNX may offer the potential to reduce hospital costs and length of stay Ut
Slide 61: IV Status Epilepticus: 2023 Expansion and Key Assumptions
©2021 Marinus Pharmaceuticals. All Rights Reserved I IV Status Epilepticus: 2023 Expansion and Key Assumptions Initial Analog/Overlapping Analysis x Reviewed status epilepticus claims x 24 - hour EEG monitoring x Tertiary and quaternary care centers 800 - 1,000 targeted accounts for launch Proposed
Slide 62: Differentiated Market Access Strategy for IV Ganaxolone
©2021 Marinus Pharmaceuticals. All Rights Reserved I Differentiated Market Access Strategy to Ensure Success for IV Ganaxolone Formulation • U.S./EU Pricing research initiated and ongoing • Determining New Technology Add - on Payment (NTAP) timing • Evaluating DRGs and other hospital payment systems
Slide 63: Financial Update
Financial Update
Slide 64: Financial Overview: Q3 2021
©2021 Marinus Pharmaceuticals. All Rights Reserved I Financial Overview: Q3 2021 Analyst Coverage*: • Cantor Fitzgerald: Alethia Young • Cowen: Joseph Thome , Ph.D. • H.C. Wainwright & Co: Douglas Tsao • Jefferies: Andrew Tsai • JMP Securities: Jason N. Butler, Ph.D. • Ladenburg Thalmann : Michael H
Slide 65: Liquidity Overview
©2021 Marinus Pharmaceuticals. All Rights Reserved I Completed Sept. 2021 Completed July 2021 Liquidity Overview 1 All values shown are expected gross transactional proceeds 2 Upfront funds received, but subject to certain recoupment provisions associated with additional pre - clinical testing 3 202
Slide 66: Orion Corporation EU Partnership
©2021 Marinus Pharmaceuticals. All Rights Reserved I Established 1917; >$1billion revenue; > 3,000 employees Solid partnership and collaboration approach across alliance base Commercial presence in 28 European and CIS countries; 700 field sales professionals Active collaboration with epilepsy KOLs a
Slide 67: Credit Financing Overview
©2021 Marinus Pharmaceuticals. All Rights Reserved I Credit Financing Overview Credit financing agreement with Oaktree Capital Management , a leader among investment managers specializing in alternative investments Financing has potential to provide incremental cash of up to $125 million total throu
Slide 68: Intellectual Property
Intellectual Property
Slide 69: Multiple Layers Of Potential Protection
©2021 Marinus Pharmaceuticals. All Rights Reserved I 69 Multiple Layers Of Potential Protection Patents/ Patent Applications / Orphan Drug Designations Expiration Date Status Epilepticus Formulation Licensed Captisol ® patents Through 2033 Applications pending on IV formulation 2036 Method of Use Ap
Slide 70: Appendix
Appendix MARINUS
Slide 71: CDKL5 Deficiency Disorder & Tuberous Sclerosis Complex Oral Suspension
CDKL5 Deficiency Disorder & Tuberous Sclerosis Complex Oral Suspension
Slide 72: Subject Baseline Demographics & Country Enrollment in Marigold Study
©2021 Marinus Pharmaceuticals. All Rights Reserved I 72 Subject Baseline Demographics & Country Enrollment in Marigold Study (CDD) Demographic Placebo (n=51) Ganaxolone (n=50) Total (n=101) Age, median 7.0 5.0 6.0 Gender, n (%) Male 10 (19.6) 11 (22.0) 21 (20.8) Female 41 (80.4) 39 (78.0) 80 (79.2)
Slide 73: TSC Phase 2 Comparison to Marigold Study
©2021 Marinus Pharmaceuticals. All Rights Reserved I 73 TSC Phase 2 Comparison to Marigold Study (CDD Phase 3) *Double - blind ganaxolone subjects *
Slide 74: Status Epilepticus Intravenous Ganaxolone
©2021 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus Intravenous Ganaxolone
Slide 75: Patient Demographics of Phase 2 RSE Trial
©2021 Marinus Pharmaceuticals. All Rights Reserved I 75 Patient Demographics of Phase 2 RSE Trial 8 males, 9 females Mean age: 57 years old (range: 23 - 88) 5 (29%) CSE, 11 (65%) NCSE, 1 (6%) CSE→NCSE 7 (41%) yes, 10 (59%) no 17 patients enrolled Types of SE History of Epilepsy Mean # of failed 2nd
Slide 76: Details on Baseline Patient Characteristics for Phase 2 RSE Trial
©2021 Marinus Pharmaceuticals. All Rights Reserved I 76 NCSE: Non - convulsive status epilepticus CSE: Convulsive status epilepticus LAC: Lacosamide LEV: Levetiracetam LOR: Lorazepam PHT: Phenytoin fPHT: Fosphenytoin VPA: Valproic Acid Details on Baseline Patient Characteristics for Phase 2 RSE Tria
Slide 77: RAISE Trial Sites Standard of Care Progression to IV Anesthesia
©2021 Marinus Pharmaceuticals. All Rights Reserved I RAISE Trial Sites Standard of Care Progression to IV Anesthesia ► Surveyed PI’s at selected RAISE Trial sites to learn more about their standard of care natural history progression to IV anesthesia following the failure of one versus more than one
Slide 78: BARDA Contract – Refractory Status Epilepticus
©2021 Marinus Pharmaceuticals. All Rights Reserved I 78 BARDA Contract – Refractory Status Epilepticus Key Contract Parameters ► Biomedical Advanced Research and Development Authority (BARDA) to contribute $21 million in base contract to support the Phase 3 RAISE clinical trial in RSE and preclinica
Marinus Pharmaceuticals — Q3 2021 Earnings Presentation on 6ix